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Background
The clinical benefit of Therapeutic Drug Monitoring
(TDM) of mycophenolate mofetil (MMF) when used in
children with lupus (SLE) has been scarcely studied.
Aim
(i) To model mycophenolic acid (MPA; the active moi-
ety of MMF) pharmacokinetic profiles (PK); (ii) to
explore the relationships between exposure indices to
MPA and the clinical status.in paediatric inpatients with
SLE receiving a maintenance immunosuppressive ther-
apy including MMF.
Methods
We launched a non-interventional study with analysis of
clinical, biological and pharmacokinetic information.
Full-PK profiles of MPA were modelled using an itera-
tive two-stage approach (1). The clinical status was
defined by the SLEDAI, the SLE being considered active
for a score ≥6. Relationships between MPA through
concentrations (C0), AUC (Area Under Curve) or AUC/
dose values, and the disease’s activity were studied using
logistic regression analysis.
Results
Twenty six children (aged 10 to 17) with SLEDAI
score from 0 to 20 (median: 4) followed-up in 5
French centres were included. High PK interpatient
variability was observed: AUC0-12h=40.51±20.49 mg.h/
L. Trough concentrations (C0) were poorly correlated
to the global exposure to MPA (AUC). Multivariate
analysis reported: (i) no relationship between C0 and
SLEDAI; (ii) patients with an AUC0-12h/dose <0.058 h/
L were more likely to have an active disease (OR=4.8;
95CI: 0.9-25.0; p=0.067).
Conclusion
A tendency to a relationship between the lupus activity
and the global MPA exposure was observed. Further
data are needed to develop PK tools that could estimate
the AUC using a limited sampling strategy and to lead
prospective trials testing the clinical impact of a MMF
TDM based on the AUC.
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